/BXRX
BXRX Stock - Baudax Bio, Inc.
Healthcare|BiotechnologyNASDAQ
$0.02+7.39%
+$0.00 (+7.39%) • Feb 29
47
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.5
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.57
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.02
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BXRX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.02 – $0.02
TARGET (TP)$0.03
STOP LOSS$0.02
RISK/REWARD1:4.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.58
52W High$3.47
52W Low$0.01
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $1.27M | $1.08M | $493,000 | N/A | N/A |
| Gross Profit | $-5,740,000 | $-1,365,000 | $-1,239,000 | N/A | N/A |
| Gross Margin | -452.3% | -126.4% | -251.3% | N/A | N/A |
| Operating Income | $-35,743,000 | $-19,006,000 | $-74,786,000 | $-32,519,000 | $-73,535,000 |
| Net Income | $-58,795,000 | $-19,769,000 | $-76,100,000 | $-18,003,000 | $-73,667,000 |
| Net Margin | -4633.2% | -1830.5% | -15436.1% | N/A | N/A |
| EPS | $-177.30 | $-361.16 | $-5715.36 | $-2695.87 | $-11361.35 |
Company Overview
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
BXRXBeat Rate
56%
Last 16 quarters
Avg Surprise
-7.6%
EPS vs Estimate
Beats / Misses
9/5
2 met exactly
Latest EPS
$-0.29
Q4 2023
EPS Surprise History
Q1 22
+580.0%
$401.20vs$59.00
Q2 22
-71.4%
$-126.80vs$-74.00
Q3 22
+17.3%
$-42.00vs$-50.80
Q4 22
-366.0%
$-98.80vs$-21.20
Q1 23
-226.3%
$-12.33vs$9.76
Q2 23
-155.5%
$-3.19vs$5.75
Q3 23
+27.0%
$-1.49vs$-2.04
Q4 23
+45.3%
$-0.29vs$-0.53
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2023 | Nov 20, 2023 | $-0.53 | $-0.29 | +45.3% | ✓ BEAT |
Q3 2023 | Aug 16, 2023 | $-2.04 | $-1.49 | +27.0% | ✓ BEAT |
Q2 2023 | May 12, 2023 | $5.75 | $-3.19 | -155.5% | ✗ MISS |
Q1 2023 | Feb 23, 2023 | $9.76 | $-12.33 | -226.3% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-21.20 | $-98.80 | -366.0% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-50.80 | $-42.00 | +17.3% | ✓ BEAT |
Q2 2022 | May 4, 2022 | $-74.00 | $-126.80 | -71.4% | ✗ MISS |
Q1 2022 | Mar 16, 2022 | $59.00 | $401.20 | +580.0% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $-223.78 | $-279.72 | -25.0% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-307.69 | $-293.71 | +4.5% | ✓ BEAT |
Q2 2021 | May 5, 2021 | $-265.73 | $-265.73 | 0.0% | = MET |
Q1 2021 | Feb 16, 2021 | $-849.33 | $-770.00 | +9.3% | ✓ BEAT |
Q4 2020 | Nov 9, 2020 | $-1174.83 | $-1006.99 | +14.3% | ✓ BEAT |
Q3 2020 | Aug 10, 2020 | $-1034.97 | $-1034.97 | 0.0% | = MET |
Q2 2020 | May 8, 2020 | $-1272.73 | $-1160.84 | +8.8% | ✓ BEAT |
Q1 2020 | Feb 13, 2020 | $-1311.33 | $-1092.00 | +16.7% | ✓ BEAT |
Q4 2019 | Nov 14, 2019 | — | $-1590.84 | — | — |
Q4 2019 | Nov 12, 2019 | — | $-1632.02 | — | — |
Q1 2019 | Mar 31, 2019 | — | $-668.57 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-2572.64 | — | — |
Latest News
Loading news...
Frequently Asked Questions about BXRX
What is BXRX's current stock price?
Baudax Bio, Inc. (BXRX) is currently trading at $0.02 per share. The stock has moved +7.39% today.
What is the analyst price target for BXRX?
No analyst price targets are currently available for this stock.
What sector is Baudax Bio, Inc. in?
Baudax Bio, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is BXRX's market cap?
Baudax Bio, Inc. has a market capitalization of N/A, making it a small-cap company.
Does BXRX pay dividends?
No, Baudax Bio, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBLCM
Bellicum Pharmaceuticals, Inc.
$0.07
Mkt Cap: $0.0B
CWBR
CohBar, Inc.
$0.41
Mkt Cap: $0.0B
CYTO
Altamira Therapeutics Ltd.
$0.30
Mkt Cap: $0.0B
IMPL
Impel Pharmaceuticals Inc.
$0.04
Mkt Cap: $0.0B
INFIQ
Infinity Pharmaceuticals, Inc.
$0.00
Mkt Cap: $0.0B
LSDI
Lucy Scientific Discovery Inc.
$0.51
Mkt Cap: $0.0B
NMTRQ
9 Meters Biopharma, Inc.
$0.00
Mkt Cap: $0.0B
NVIV
InVivo Therapeutics Holdings Corporation
$0.32
Mkt Cap: $0.0B
TMBR
Timber Pharmaceuticals, Inc.
$0.34
Mkt Cap: $0.0B
YCBD
cbdMD, Inc.
$1.51
Mkt Cap: $0.0B
Explore stocks similar to BXRX for comparison